New weekly insulin reduces injections
The U.S. Food and Drug Administration has approved Ounswik, a medication developed by Eli Lilly. It is a basal insulin administered once weekly to patients with type 2 diabetes, serving as an alternative to the daily long-acting injections. The medication has demonstrated efficacy comparable to daily insulin in lowering blood sugar levels and has achieved positive results in clinical trials involving over 3,400 adults, while reducing the number of annual injections by more than 300. The new insulin is used alongside diet and exercise but is not intended for people with type 1 diabetes due to increased risks of low blood sugar. The drug is available in the United States as a pen in two concentrations: 500 units/milliliter and 1000 units/milliliter. This represents an important step toward improving diabetes management and decreasing the number of daily injections.
Notice: This Is an AI-Generated Summary
Comments (0)